Second Sight Medical Product has completed a merger with Nano Precision Medical, which is developing a GLP-1 receptor agonist to treat patients with type 2 diabetes for six months with a single tiny subcutaneous implant. Shareholders of Nano Precision Medical received 23% of the combined company, which is now called Vivani Medical and trades under the ticker symbol VANI.